Pfizer Faces Multidistrict Litigation in the US Over Depo-Provera's Alleged Link to Brain Tumors

Reuters
2025/05/28
Pfizer Faces Multidistrict Litigation in the US Over Depo-Provera's Alleged Link to Brain Tumors

Pfizer Inc. is currently facing a multidistrict litigation in the United States involving approximately 400 lawsuits related to its contraceptive injection, Depo-Provera. The lawsuits allege that Pfizer failed to adequately warn women in the U.S. about the increased risk of developing brain tumors, specifically meningiomas, after prolonged use of the drug. This legal action comes in the wake of a study published in March 2024 by EPI-PHARE in the British Medical Journal, which found that women using Depo-Provera for over a year were 5.6 times more likely to develop intracranial meningiomas. Despite adding warning labels in Canada, the UK, and Europe, Pfizer has not issued similar warnings in the U.S. A Case Management Conference is scheduled for May 30 in Pensacola, Florida, as part of the proceedings. The litigation is being supported by the law firm Levin Papantonio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250526151184) on May 28, 2025, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10